|
Found 21 result(s) FROM 1963 pages containing the term 'arterial stiffness'.
Tuesday Nov 17, 2009
Inflammation in RA Linked to Arterial Stiffness
RA patients with high inflammatory burden are more likely to have arterial stiffness, even without other known cardiovascular risk factors...
Wednesday Aug 19, 2009
Echo Urged to Rule Out PAH in High-Risk Lupus
Echocardiogram screening may be useful in identifying pulmonary arterial hypertension in high risk lupus patients...
Monday Nov 17, 2008
Vitamin D Levels Linked to OA Cartilage Loss, OA Pain, and SSc Disease Activity by ACR Researchers
Low vitamin D levels are associated with faster progression of joint damage, bone loss, and pain in OA and with higher levels of inflammatory markers and vascular complications in systemic sclerosis, suggesting that more attention to vitamin D supplements might be in order...
Monday Jul 28, 2008
NHS TNF Inhibitor Restrictions Heighten Impact of Baseline DAS28 in RA
The British National Institute for Health and Clinical Excellence (NICE) guidelines for approving access to TNF inhibitors for patients with rheumatoid arthritis (RA) may be unnecessarily extending the period when steroids are not allowed and classifying >30% of patients as “nonresponders” who would not be allowed to continue anti-TNF treatment...
Friday Jul 25, 2008
New High-Resolution Device Aids Finger MRI in Scleroderma
High-resolution magnetic resonance angiography (micro-MRA) can readily measure vascular disease of fingers in systemic sclerosis…
Thursday Jul 24, 2008
Lupus No Longer Seen As Complete Contraindication to Oral Contraceptive Use
Oral contraceptives, long considered a risk for women with systemic lupus erythematosus (SLE), are now often considered for women with inactive or stable SLE…
Thursday Apr 17, 2008
PAH Differs in Connective Tissue Diseases
Patients with PAH due to connective tissue disease have more dysfunctional pulmonary capillary endothelium than those with PAH from other causes...
Thursday Mar 20, 2008
Two-Pronged Strategy for Treating PAH in Lupus or Mixed Connective Tissue Disease
Lupus or MCTD patients with pulmonary arterial hypertension (PAH) should be treated with cyclophosphamide and glucocorticoids, with added pulmonary vasodilators in more severe cases...
Tuesday Oct 09, 2007
Sitaxsentan May Offer Alternative to Bosentan for PAH in Connective Tissue Disease Patients
Sitaxsentan improved 6-minute walk distance and quality of life in connective tissue disease patients who also have PAH...
Thursday Sep 13, 2007
Hormone Therapy Does Not Worsen Lupus But May Increase Thrombosis Risk
Menopause hormonal therapy does not worsen lupus disease activity or trigger disease flares but may add to an already high risk of thrombosis in women with SLE...
Wednesday Sep 05, 2007
Rheumatologists Asked to Take Lead in Reducing Cardiovascular Risk in RA Patients
The chronic inflammation that characterizes many rheumatoid diseases is thought to be one cause of the higher rates of cardiovascular disease (CVD) that afflicts these patients. Experts say not enough is being done to educate patients with rheumatoid arthritis (RA) or with systemic lupus erythematosus (SLE) about the importance of early CV protection, and that early education is critical—before clinically apparent CVD is detectable...van Leuven SI, et al. Rheumatology. 2007; rheumatology/kem202 [Epub ahead of print]; John H, et al. Rheumatology. 2007; doi:10.1093/rheumatology/kem176 [Epub ahead of print].
Thursday Jun 14, 2007
Modifed-Release Prednisone Tablet Reduces Morning Stiffness
Study highlights new approach to prednisolone delivery that synchronizes with the circadian rhythms of endogenous cortisol and RA symptoms…
Monday Feb 12, 2007
Etoricoxib Reduces Mild but Not Serious GI Events Versus Diclofenac
The gradual return of the coxibs gained traction this week with a report in The Lancet that etoricoxib produced significantly fewer upper GI clinical events than diclofenac in RA or OA patients in the randomized MEDAL program studies...
Monday Dec 18, 2006
Smoking Exacerbates Knee OA
Men with knee osteoarthritis (OA) who smoke experience greater cartilage loss and more severe pain than men who do not smoke…Amin S, et al. Ann Rheum Dis. 2006 December 20; [Epub ahead of print].
Thursday Sep 07, 2006
Overall Lupus Mortality Drops, but SLE Cardiovascular Death Rates Increase
As death rates continue to plummet in systemic lupus erythematosus (SLE), physicians need to treat cardiovascular symptoms aggressively while balancing the need for immune suppressant therapy against the risk of fatal infection... Bernatsky S, et al. Arthritis Rheum. 2006;54:2550-2557
Tuesday Jun 27, 2006
Bosentan Prevents Digital Ulcers, Improves Heart Function in Systemic Sclerosis
Bosentan reduces digital ulcer risk and improves heart function in systemic sclerosis patients... Allanore Y, et al. Presented at: EULAR 2006 Meeting; June 21–34, 2006; Amsterdam, The Netherlands. Abstract OP0120.
Thursday Jan 12, 2006
Three Months of Bosentan Therapy Improves Function in SSc-PAH Patients
Three Months of Bosentan Therapy Improves Function in SSc-PAH Patients
Wednesday Jan 11, 2006
NicOx Initiates Phase III for HCT 3012, Naproxen Derivative for Osteoarthritis
NicOx SA, a French biopharmaceutical company focused on the development of nitric-oxide-donating drugs to treat inflammation, pain, and cardio-metabolic disease...
Friday Oct 07, 2005
Marked Decrease in Pregnancy Loss Seen in Women with Lupus
Largely due to improvements in perinatal monitoring and disease management, there has been a significant decrease in pregnancy loss among women with systemic lupus erythematosus over the past 40 years . . . Clark CA, et al. J Rheumatol. 2005;32:1709-1712.
Wednesday May 04, 2005
CoTherix's Treatment for Pulmonary Arterial Hypertension Reaches Market
CoTherix, Inc, has recently announced the commercial availability of VentavisR (iloprost) Inhalation Solution, for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms. Approved by the US Food and Drug Administration in December 2004, Ventavis, an inhaled formulation of iloprost that is structurally similar to prostacyclins, provides PAH patients with a noninvasive treatment option that avoids the complications associated with intravenous or subcutaneous prostacyclin delivery. A recognized complication of lupus, PAH can be life-threatening and require heart-lung transplantation. Ventavis, licensed from Schering AG, is currently marketed by Schering AG in several European countries and Australia. - Nicholas K. Zittell
Friday Feb 18, 2005
European Medicines Agency Calls Cardiovascular Risk a Class Effect of Coxibs
EMEA calls for stricter labeling and restricted use for COX-2 inhibitors... will the FDA follow suit? EMEA press release. London, UK; February 17, 2005.
|
